Lactobacillus brevis G-101 ameliorates colitis in mice by inhibiting NF-κB, MAPK and AKT pathways and by polarizing M1 macrophages to M2-like macrophages
Open Access
- 6 June 2013
- journal article
- research article
- Published by Oxford University Press (OUP) in Journal of Applied Microbiology
- Vol. 115 (3) , 888-896
Abstract
Aim We isolated Lactobacillus brevis G‐101 from kimchi lactic acid bacteria (LAB) strains, which induced IL‐10 expression in lipopolysaccharide (LPS)‐stimulated peritoneal macrophages. To evaluate the inflammatory effect of G‐101, we examined its inhibitory effect in 2,4,6‐trinitrobenzene sulfonic acid (TNBS)‐induced colitic mice. Materials and Results The colitic mice were prepared by intrarectal injection of TNBS. We measured intestinal mucosal cytokines by enzyme‐linked immunosorbent assay; activation of transcription factors, by immunoblotting; and macrophage polarization markers, by real‐time polymerase chain reaction. Of 200 LAB strains tested, Lact. brevis G‐101 showed most potent activity for induction of IL‐10 expression in LPS‐stimulated peritoneal macrophages. However, it significantly inhibited the expression of TNF‐α, IL‐1β and IL‐6 and the phosphorylation of IRAK1 and AKT, and activated NF‐κB and MAPKs. Treatment with TNBS caused colon shortening; increased myeloperoxidase activity; and increased IL‐1β, IL‐6 and TNF‐α expression in mice. Oral administration of Lact. brevis G‐101 significantly inhibited these activities. Lactobacillus brevis G‐101 inhibited TNBS‐induced IRAK‐1 phosphorylation and NF‐κB activation, as well as the expression of COX‐2 and iNOS. Lactobacillus brevis G‐101 inhibited the expression of M1 macrophage markers, but increased the expression of M2 macrophages in the colons of TNBS‐treated mice. Conclusions Lactobacillus brevis G‐101 may improve colitis by inhibiting the IRAK1/NF‐κB, MAPK and AKT pathways and by polarizing M1 macrophages to M2‐like macrophages. Significance and Impact of the Study These results suggest that IL‐10 expression‐inducing LAB can ameliorate colitis by inhibiting NF‐κB activation and macrophage polarization.Keywords
This publication has 31 references indexed in Scilit:
- Systematic validation of specific phenotypic markers for in vitro polarized human macrophagesJournal of Immunological Methods, 2012
- Lactobacillus casei prevents the development of dextran sulphate sodium-induced colitis in Toll-like receptor 4 mutant miceClinical and Experimental Immunology, 2007
- Inflammatory bowel disease: dysfunction of GALT and gut bacterial flora (II)The Surgeon, 2003
- Differential Alteration in Intestinal Epithelial Cell Expression of Toll-Like Receptor 3 (TLR3) and TLR4 in Inflammatory Bowel DiseaseInfection and Immunity, 2000
- Toll-like receptors in the induction of the innate immune responseNature, 2000
- Probiotics in inflammatory bowel disease: New insight to pathogenesis or a possible therapeutic alternative?Gastroenterology, 1999
- Toll-like Receptor-4 Mediates Lipopolysaccharide-induced Signal TransductionJournal of Biological Chemistry, 1999
- THE NF-κB AND IκB PROTEINS: New Discoveries and InsightsAnnual Review of Immunology, 1996
- Functional Alterations of the Microflora in Patients with Ulcerative ColitisScandinavian Journal of Gastroenterology, 1993
- A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye bindingAnalytical Biochemistry, 1976